Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find Clinical Trials & Studies

APOL1-mediated Proteinuric Kidney Disease

I'm Interested!

Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease

  • Sex at Birth: Any
  • Age: Adult (18 - 64)
  • Accepting Healthy People: No
  • Type: Interventional / Therapeutic
  • Trial Phase: Phase II/III
  • Conditions Being Studied: Apolipoprotein L1

Study Purpose

This study is enrolling participants who may have APOL1-mediated Chronic Kidney Disease. This means you may have increased levels of protein in the urine because your kidneys are not working properly. This condition may or may not be attributed to having a genetic variation (changes in DNA) in a gene called APOL1. Certain people with variants in the APOL1 gene have a higher risk of kidney disease. People of recent African ancestry are more likely to have certain APOL1 variants and are more at risk for CKD. You may never have been tested for APOL1 and therefore do not know if your kidney disease is caused or affected by having the APOL1 variation. This study is being done to learn more about the safety and effectiveness of the investigational drug VX-147 in participants with APOL1-Mediated Chronic Kidney Disease.

Principal Investigator
Lavinia Negrea MD
Department/Division
Nephrology (Medicine)

Locations

UH Minoff Health Center at Chagrin Highlands
3909 Orange Place
Orange Village OH, 44122

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

  • UH IRB: STUDY20230016
  • StudyID: 2022-01032
  • ClinicalTrials.gov: NCT05312879
I'm Interested!

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422